X4制药 XFOR 深 沪
等待开盘 05-21 09:30:00 美东时间
3.81
+0.170
+4.67%
华盛通- 最 高3.85
- 今 开3.65
- 成交量 17.85万股
- 最 低 3.5801
- 昨 收 3.64
- 总市值 3.59亿
- 52周最高 4.83
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 1.35
- 委 比 -53.70%
- 总股本 9431.97万
- 历史最高 717.90
- 量 比 0.72
- 振 幅 7.41%
- 历史最低 2.83
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 500 percent decrease over earnings of $0.04 per share from the
05-06 19:51
X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia -BOSTON, April 29, 2026 (GLOBE
04-29 19:14
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals issued inducement awards to new employees, totaling 32,000 stock options, under the 2019 Inducement Plan, approved by its Compensation Committee. The options have a $4.13 exercise price, a 10-year term, and vest over four years, with 25% after 12 months and the remainder monthly over 36 months. X4, based in Boston, focuses on treating rare hematologic diseases and is advancing mavorixafor, which has received FDA Fast Track desi...
04-01 20:30
X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice
X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice X4 Pharmaceuticals will hold its annual meeting virtually on May 11, 2026. Shareholders will vote to elect three Class III director nominees to serve until the 2029 annual meeting. The meeting agenda also includes ratifying Pricewa
03-20 20:46
Rare disease drugmaker X4 Pharma's Q4 revenue rises on XOLREMDI strength
Rare disease drugmaker X4 Pharma's Q4 revenue rises on XOLREMDI strength Overview Rare hematology drug developer's Q4 revenue reached $2.6 mln, driven by XOLREMDI sales and licensing Company posted Q4 net loss of $23.9 mln, or $0.22 per share Cash runway projected through 2028 after equity financing
03-17 19:29
X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of $(5.89) per share
03-17 19:18
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its financial results for Q4 and FY 2025, highlighting progress in its 4WARD trial for chronic neutropenia, positive EMA opinion for mavorixafor in WHIM syndrome, and strong cash runway through 2028.
03-17 11:15
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026, at 10:00 a.m. ET in Miami, FL. The company, focused on improving lives through innovative therapies for rare hematologic diseases, is currently conducting a Phase 3 trial for its CXCR4 antagonist, mavorixafor, in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation for this treatment. More details and a w...
03-04 12:00
